Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
20/20 BiolabsAIDX -0.23%6 OCF Yield % is -34.51 as of Aug. 03, 2026. GuruFocus rates AIDX with a GF Score™ of 6/100. The stock has 1 warning sign investors should review. Among 850 Medical Devices & Instruments companies, 20/20 Biolabs ranks worse than 89.06% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
20/20 Biolabs OCF Yield % Related Terms
20/20 Biolabs OCF Yield % Historical Data
* Premium members only.
The historical data trend for 20/20 Biolabs's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, 20/20 Biolabs's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
20/20 Biolabs OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, 20/20 Biolabs's OCF Yield % distribution charts can be found below:
* The bar in red indicates where 20/20 Biolabs's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
20/20 Biolabs (AIDX) has a OCF Yield % of -34.51 as of Aug. 03, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on 20/20 Biolabs and its competitors. According to the industry distribution chart, 20/20 Biolabs ranks #757 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 89.1%.
Is 20/20 Biolabs' OCF Yield % too high?
20/20 Biolabs' current OCF Yield % is -34.51. Based on the distribution chart, 20/20 Biolabs ranks #757 out of 850 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, 20/20 Biolabs has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does 20/20 Biolabs' OCF Yield % compare to STME and TRIB?
According to the Medical Devices & Instruments industry distribution chart, 20/20 Biolabs ranks #757 out of 850 companies for OCF Yield %. This places 20/20 Biolabs in the lower half of its industry. The industry median OCF Yield % is 1.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.68, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on 20/20 Biolabs and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 20/20 Biolabs's current OCF Yield % is -34.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 20/20 Biolabs stock overvalued right now?
20/20 Biolabs (AIDX) has a current OCF Yield % of -34.51. The current OCF Yield % is -34.51. 20/20 Biolabs' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For 20/20 Biolabs (AIDX), the current OCF Yield % is -34.51 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
6GF Score
Get the complete analysis for AIDX
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIDX has been successfully added to your 
